Sam Schulman, MD, PhD; Sameer Parpia, MSc; Clare Stewart, MA; Lisa Rudd-Scott, RN, BScN; Jim A. Julian, MMath; Mark Levine, MD, MSc
Schulman S, Parpia S, Stewart C, Rudd-Scott L, Julian JA, Levine M. Warfarin Dose Assessment Every 4 Weeks Versus Every 12 Weeks in Patients With Stable International Normalized Ratios: A Randomized Trial. Ann Intern Med. 2011;155:653-659. doi: 10.7326/0003-4819-155-10-201111150-00003
Download citation file:
Published: Ann Intern Med. 2011;155(10):653-659.
Guidelines recommend that patients receiving warfarin undergo international normalized ratio (INR) monitoring every 4 weeks.
To investigate whether assessment of warfarin dosing every 12 weeks is as safe as assessment every 4 weeks.
Noninferiority randomized trial. The randomization schedule (in a 1:1 ratio) was computer-generated, and allocation was concealed until the database was locked by using a centralized schedule. Patients, study and clinical personnel, adjudicators of clinical events, and the study statistician were blinded to treatment assignment. (ClinicalTrials.gov registration number: NCT00356759)
Single center in Hamilton, Ontario, Canada.
250 patients receiving long-term warfarin therapy, whose dose was unchanged for at least 6 months; 226 completed the study.
Dosing assessment every 12 weeks (n = 124) compared with every 4 weeks (n = 126) for 12 months. Patients in the 12-week group were tested every 4 weeks; sham INRs within the target range were reported for two of the three 4-week periods.
Percentage of time in the therapeutic range (primary outcome) and number of extreme INRs, changes in maintenance dose, major bleeding events, objectively verified thromboembolism, and death (secondary outcomes).
The percentage of time in the therapeutic range was 74.1% (SD, 18.8%) in the 4-week group compared with 71.6% (SD, 20.0%) in the 12-week group (absolute difference, 2.5 percentage points [1-sided 97.5% upper confidence bound, 7.3 percentage points]; noninferiority P = 0.020 for a 7.5–percentage point margin). Fewer patients in the 12-week group than in the 4-week group had any dose changes (37.1% vs. 55.6%; absolute difference, 18.5 percentage points [95% CI, 6.1 to 30.0 percentage points]; P = 0.004). Secondary outcomes did not differ between groups.
Patients in the 12-week group had testing and contact with clinic staff every 4 weeks. The study was conducted at a single center and used surrogate outcomes.
Assessment of warfarin dosing every 12 weeks seems to be safe and noninferior to assessment every 4 weeks. A comparison of INR testing, patient contact, and warfarin dose assessment every 12 weeks versus every 4 weeks is necessary before INR testing every 12 weeks can be routinely recommended for practice.
Physicians' Services Incorporated Foundation.
Current guidelines recommend international normalized ratio (INR) monitoring and warfarin dose assessments every 4 weeks.
In this trial comparing warfarin dosing assessment every 4 weeks versus every 12 weeks among patients whose warfarin dose had been unchanged for at least 6 months, the proportion of time that patients were within the target INR range did not significantly differ between groups.
Patients in the group that had dose assessments every 12 weeks had INR testing and supportive contact with clinic staff every 4 weeks.
Extending the warfarin dosing assessment interval from every 4 to every 12 weeks is probably safe for patients receiving stable doses of warfarin if they continue to have supportive contact with anticoagulation clinic staff every 4 weeks. The findings should not be interpreted to mean that extending INR monitoring to every 12 weeks is proven safe.
R = randomization.
INR = international normalized ratio; TTR = time in therapeutic range.
INR = international normalized ratio.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Cardiology, Heart Failure, Hematology/Oncology, Hospital Medicine, Prevention/Screening.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only